Article Details

Pfizer might buy BMS for $130bn – but should it?

Retrieved on: 2018-02-22 20:22:30

Tags for this article:

Click the tags to see associated articles and topics

Pfizer might buy BMS for $130bn – but should it?. View article details on hiswai:

Excerpt

<div>“We believe that regulatory-grade real-world evidence is a key ingredient to accelerate the development of, and access to, new cancer treatments. As a leading technology company in oncology, <b>Flatiron Health</b> is best positioned to provide the technology and data analytics infrastructure needed not only ...</div>

Article found on:

View Original Article

This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.

Sign Up
Book a Demo